Kala Pharmaceuticals Announces New Drug Application For KPI-121 0.25% For Dry Eye Disease Has Been Accepted For Review By The U.S. Food And Drug Administration by mparnell | Dec 26, 2018 | Portfolio News
Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan by mparnell | Dec 21, 2018 | Portfolio News
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17 by mparnell | Dec 21, 2018 | Portfolio News
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults by mparnell | Dec 20, 2018 | Portfolio News
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods by mparnell | Dec 20, 2018 | Portfolio News
